Login / Signup
Letter to the Editor: Aspirin and GLP-1RAs-The missing confounders of empagliflozin for MASLD without diabetes mellitus?
Yue Hu
Zheng Li
Zhiping Li
Yaqin Zhao
Qing Liu
Qingfang Li
Xinran Cheng
Published in:
Hepatology (Baltimore, Md.) (2024)
Keyphrases
</>
low dose
wild type
cardiovascular events
antiplatelet therapy
glycemic control
anti inflammatory drugs
type diabetes
acute coronary syndrome
coronary artery disease
percutaneous coronary intervention
metabolic syndrome